WO2000067767A1 - Poplar bud extract and its combination with squalane as anti-inflammatory medicine - Google Patents
Poplar bud extract and its combination with squalane as anti-inflammatory medicine Download PDFInfo
- Publication number
- WO2000067767A1 WO2000067767A1 PCT/FR2000/001222 FR0001222W WO0067767A1 WO 2000067767 A1 WO2000067767 A1 WO 2000067767A1 FR 0001222 W FR0001222 W FR 0001222W WO 0067767 A1 WO0067767 A1 WO 0067767A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poplar
- extract
- squalane
- combination
- esters
- Prior art date
Links
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 title abstract description 68
- 241000219000 Populus Species 0.000 title abstract description 43
- 239000000284 extract Substances 0.000 title abstract description 40
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 title abstract description 32
- 229940032094 squalane Drugs 0.000 title abstract description 32
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 11
- 239000003814 drug Substances 0.000 title abstract description 11
- 239000002537 cosmetic Substances 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 10
- 241000218982 Populus nigra Species 0.000 abstract description 8
- 235000009048 phenolic acids Nutrition 0.000 abstract description 7
- 150000007965 phenolic acids Chemical class 0.000 abstract description 7
- 235000013824 polyphenols Nutrition 0.000 abstract description 7
- 230000002009 allergenic effect Effects 0.000 abstract description 6
- -1 phenolic acid esters Chemical class 0.000 abstract description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 230000000699 topical effect Effects 0.000 abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 229940100601 interleukin-6 Drugs 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 235000004883 caffeic acid Nutrition 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 210000002510 keratinocyte Anatomy 0.000 description 7
- 102000008070 Interferon-gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 229960003130 interferon gamma Drugs 0.000 description 6
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229940074360 caffeic acid Drugs 0.000 description 5
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 210000000416 exudates and transudate Anatomy 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- 241000241413 Propolis Species 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940069949 propolis Drugs 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- PVJNLMXWZXXHSZ-UHFFFAOYSA-N 3,5-dihydroxy-7-methoxy-2-phenylchromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 PVJNLMXWZXXHSZ-UHFFFAOYSA-N 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000168036 Populus alba Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 2
- DEDGUGJNLNLJSR-UHFFFAOYSA-N hydroxycinnamic acid group Chemical class OC(C(=O)O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 description 2
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000014666 liquid concentrate Nutrition 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- URFCJEUYXNAHFI-CYBMUJFWSA-N (2r)-5,7-dihydroxy-2-phenyl-2,3-dihydrochromen-4-one Chemical compound C1([C@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=CC=C1 URFCJEUYXNAHFI-CYBMUJFWSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XHCYBIGJUPTJRR-UHFFFAOYSA-N OC(=O)CC(C(O)=O)S(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O.CCCCCCCCCCCC[Na] XHCYBIGJUPTJRR-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000201976 Polycarpon Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000218998 Salicaceae Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940049657 cyclomethicone 5 Drugs 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- FXPVUWKFNGVHIZ-UHFFFAOYSA-L disodium;dodecyl sulfate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O FXPVUWKFNGVHIZ-UHFFFAOYSA-L 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000012260 resinous material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Definitions
- the said invention also relates to a process for preparing said combination as well as a cosmetic treatment process comprising the topical application of said cosmetic composition.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention concerns a combination of squalane and a non-allergenic extract of poplar buds Populus nigra L containing polyphenols in amount ranging between 5 and 20 % relative to the extract dry matter, phenolic acids and practically free of any phenolic acid esters designed to be used for preparing a cosmetic composition and as medicine and particularly as anti-inflammatory medicine. The invention also concerns a method for preparing said combination and a method of cosmetic treatment consisting in a topical application of said cosmetic composition.
Description
EXTRAIT DE BOURGEONS DE PEUPLIER ET SON ASSOCIAΗON AVEC LE SQUALANE COMME MEDICAMENT ANTI-INFLAMMATOIREEXTRACT OF POPLAR BEANS AND ITS ASSOCIAΗON WITH SQUALANE AS AN ANTI-INFLAMMATORY MEDICINE
La présente invention concerne une association de squalane et d'un extrait de bourgeons de peuplier Populus nigra L. non allergisant en tant que médicament et pour son utilisation pour préparer des compositions cosmétiques. La présente invention concerne encore un procédé de préparation de ladite association.The present invention relates to a combination of squalane and a non-allergenic Populus nigra L. poplar bud extract as a medicament and for its use for preparing cosmetic compositions. The present invention also relates to a process for the preparation of said association.
Le problème posé par les extraits de bourgeons de peuplier lorsqu'on souhaite les utiliser pour préparer des compositions destinées à une application cosmétique ou thérapeutique est leur caractère allergisant. Le but de la présente invention est de proposer un extrait de bourgeon de peuplier non allergisant qui possède des propriétés anti-inflammatoires.The problem posed by poplar bud extracts when it is desired to use them to prepare compositions intended for cosmetic or therapeutic application is their allergenic nature. The object of the present invention is to provide an extract of non-allergenic poplar bud which has anti-inflammatory properties.
En outre, il a été mis en évidence que la combinaison de l'extrait de bourgeons de peuplier selon l'invention avec du squalane présente des propriétés antiinflammatoires exaltées.In addition, it has been demonstrated that the combination of the poplar bud extract according to the invention with squalane has exalted anti-inflammatory properties.
Le peuplier, Populus nigra L. appartient à la famille botanique des Salicacées. Il se distingue du peuplier blanc, Populus alba par la couleur sombre de son feuillage. Cet arbre qui peut atteindre 20 à 25 mètres, croît communément sur les terrains humides, son besoin en eau est très important. Ses rameaux sont étalés ou dressés le long de son tronc, comme c'est le cas du peuplier d'Italie ou Populus pyramidalis qui est considéré comme une variété du Populus nigra. Ses feuilles sont alternes, stipulées, simples à longs pétioles, le limbe est triangulaire finement denté. Les fleurs sont unisexuées, groupées en chatons pendants à l'aisselle des feuilles : les fleurs mâles produisent un pollen abondant, les fleurs femelles sont réduites à un seul ovaire. Le fruit est une capsule loculicide renfermant de nombreuses graines.
Les peupliers produisent des bourgeons qui se récoltent en fin d'hiver à partir de février. Ces bourgeons sont de forme ovoïde aiguë, légèrement courbés, glabres, brun clair. Ils sont rendus visqueux par une matière résineuse odorante. Ces bourgeons sont formés d'écaillés imbriquées. Les bourgeons de peuplier renferment des substances phénoliques. Ces substances sont des flavonoïdes tels que la chrysine et dérivés, la galangine, la pinocembrine et izalpinine (Egger K. Tissut M., 1968, C.R. Acad. Sci. Paris 267, 1329-1332) mais aussi de l'apigénine, quercétine, kaempférol, rhamnetine (Wollenweber E, Egger K, 1971 , Phytochemistry 10, 225- 226). La résine recouvrant ses bourgeons, véritable exsudât, a été particulièrement étudiée pour sa composition chimique.The poplar, Populus nigra L. belongs to the botanical family of Salicaceae. It is distinguished from the white poplar, Populus alba by the dark color of its foliage. This tree which can reach 20 to 25 meters, grows commonly on wet grounds, its need for water is very important. Its branches are spread out or erect along its trunk, as is the case of the Italian poplar or Populus pyramidalis which is considered to be a variety of Populus nigra. Its leaves are alternate, stipulated, simple with long petioles, the blade is triangular finely toothed. The flowers are unisexual, grouped in catkins hanging from the leaf axils: the male flowers produce abundant pollen, the female flowers are reduced to a single ovary. The fruit is a loculicidal capsule containing many seeds. Poplars produce buds which are harvested in late winter from February. These buds are acute ovoid, slightly curved, glabrous, light brown. They are made viscous by an odorous resinous material. These buds are formed of nested scales. Poplar buds contain phenolic substances. These substances are flavonoids such as chrysin and derivatives, galangin, pinocembrine and izalpinin (Egger K. Tissut M., 1968, CR Acad. Sci. Paris 267, 1329-1332) but also apigenin, quercetin, kaempferol, rhamnetine (Wollenweber E, Egger K, 1971, Phytochemistry 10, 225-226). The resin covering its buds, a real exudate, has been particularly studied for its chemical composition.
De nombreux auteurs ont décrit des esters d'acides phénoliques : esters d'acide caféique (Greenaway W, Wollenweber E, Scaysbrook T, Whatley F.R., 1988, Z. Naturforsh. 43 c, 795-798) des esters d'acide cinnamique (Bankova V.S. Popov S.S., Marekov N.L., 1989, Phytochemistry, 28, 3, 871-873). Ces auteurs ont effectué l'étude chimique comparative de l'exsudat avec la propolis et y ont trouvé ces molécules. La propolis est la résine qu'emploient les abeilles pour calfeutrer les fissures de la ruche et assurer son étanchéité à l'eau. Elle est récoltée à partir d'exsudats de différents arbres selon la proximité avec la ruche. La principale source est l'exsudat des bourgeons de peuplier. La propolis est décrite pour son allerginicité et des travaux scientifiques ont permis d'identifier les allergènes dans les exsudats de bourgeons de peuplier (Hausen M., Evers P., Stϋwe HT., Kόnig W.A., Wollenweber E., 1992, Contact Dermatitis, 26, 34-44 ; Oliwiecki S., Beck M. H., Hansen B.M., 1992, Contact Dermatitis, 27, 127-128). Les molécules responsables de ces phénomènes sont les esters d'acides phénoliques.Many authors have described phenolic acid esters: esters of caffeic acid (Greenaway W, Wollenweber E, Scaysbrook T, Whatley FR, 1988, Z. Naturforsh. 43 c, 795-798) esters of cinnamic acid ( Bankova VS Popov SS, Marekov NL, 1989, Phytochemistry, 28, 3, 871-873). These authors carried out the comparative chemical study of the exudate with propolis and found these molecules there. Propolis is the resin used by bees to seal cracks in the hive and keep it watertight. It is harvested from exudates from different trees depending on the proximity to the hive. The main source is the exudate of poplar buds. Propolis is described for its allergenicity and scientific work has made it possible to identify the allergens in the exudates of poplar buds (Hausen M., Evers P., Stϋwe HT., Kόnig WA, Wollenweber E., 1992, Contact Dermatitis, 26, 34-44; Oliwiecki S., Beck MH, Hansen BM, 1992, Contact Dermatitis, 27, 127-128). The molecules responsible for these phenomena are the esters of phenolic acids.
Les bourgeons de peuplier sont utilisés traditionnellement pour leurs propriétés antiseptiques, en usage externe ou interne, en particulier dans le cas de cystites. Ces activités sont dues aux huiles essentielles qu'ils contiennent. Traditionnellement, ils sont également utilisés comme adoucissant et anti- inflammatoire. Cette activité est également reprise en usage vétérinaire associée avec des analgésiques. Malheureusement, ces utilisations sont limitées par le potentiel allergique des bourgeons.Poplar buds are traditionally used for their antiseptic properties, for external or internal use, in particular in the case of cystitis. These activities are due to the essential oils they contain. Traditionally, they are also used as a softener and anti-inflammatory. This activity is also used in veterinary use associated with analgesics. Unfortunately, these uses are limited by the allergic potential of the buds.
Le squalane est un hydrocarbure saturé composé d'une chaîne de 30 atomes de carbone saturés. Il est obtenu par hydrogénation du squalène d'où la dénomination perhydrosqualène. Le squalène fut dans un premier temps isolé de l'huile de foie de
requin, puis, il fut identifié dans le sébum humain dans une proportion de 10% où fut également dosé du squalane à 2,5%. Le squalane de par sa structure chimique saturée est beaucoup plus stable que le squalène qui se peroxyde très facilement. Il fut donc particulièrement étudié. C'est ainsi qu'on démontre des activités émollientes, et l'industrie cosmétique l'utilise, comme tel, dans des préparations galéniques.Squalane is a saturated hydrocarbon composed of a chain of 30 saturated carbon atoms. It is obtained by hydrogenation of squalene, hence the name perhydrosqualene. Squalene was first isolated from the liver oil of shark, then it was identified in human sebum in a proportion of 10% where was also dosed with squalane at 2.5%. Squalane by its saturated chemical structure is much more stable than squalene which peroxides very easily. It was therefore particularly studied. This is how emollient activities are demonstrated, and the cosmetic industry uses it, as such, in galenical preparations.
Si l'extraction du squalane s'effectua tout d'abord à partir de foie de requin, actuellement son origine industrielle est l'huile d'olive. On le trouve également dans les huiles de germe de blé, de son, de riz ou dans les amidons d'olive.If the extraction of squalane was carried out first from shark liver, currently its industrial origin is olive oil. It is also found in the oils of wheat germ, bran, rice or in olive starches.
La présente invention concerne une association de squalane et d'un extrait de bourgeons de peuplier Populus nigra L. non allergisant contenant des polyphenols en quantité comprise entre 5 et 20% par rapport à la matière sèche de l'extrait, des acides phénoliques et qu'il ne contient pratiquement pas d'esters d'acides phénoliques (teneur inférieure à environ 0,1%) pour son utilisation pour préparer une composition cosmétique et en tant que médicament notamment en tant que médicament anti-inflammatoire.The present invention relates to a combination of squalane and an extract of populus nigra L. poplar buds non-allergenic containing polyphenols in an amount between 5 and 20% relative to the dry matter of the extract, phenolic acids and qu 'it contains practically no esters of phenolic acids (content less than about 0.1%) for its use for preparing a cosmetic composition and as a medicament in particular as an anti-inflammatory medicament.
Ladite invention concerne encore un procédé de préparation de ladite association ainsi qu'un procédé de traitement cosmétique comprenant l'application topique de ladite composition cosmétique.The said invention also relates to a process for preparing said combination as well as a cosmetic treatment process comprising the topical application of said cosmetic composition.
Les acides phénoliques auxquels il est fait référence sont plus particulièrement les acides hydroxy-cinnamiques, notamment les acides caféïque et férulique. Les esters d'acides phénoliques sont plus particulièrement les esters d'acides hydroxy- cinnamiques, notamment les esters d'acides caféïque et férulique.The phenolic acids to which reference is made are more particularly hydroxy-cinnamic acids, in particular caffeic and ferulic acids. The esters of phenolic acids are more particularly the esters of hydroxy-cinnamic acids, in particular the esters of caffeic and ferulic acids.
Les compositions d'extrait de bourgeons de peuplier et de squalane dans lesquelles la teneur en extrait de bourgeons de peuplier est comprise entre 0,1% et 5% poids et la teneur en squalane est comprise entre 0,1% et 10% poids sont préférées.The poplar bud and squalane extract compositions in which the poplar bud extract content is between 0.1% and 5% by weight and the squalane content is between 0.1% and 10% by weight are favorite.
L'extrait de bourgeons de peuplier Populus nigra L. mis en œuvre dans ladite association peut notamment être obtenu en effectuant les étapes suivantes :The populus nigra L. poplar bud extract used in said association can in particular be obtained by carrying out the following steps:
• au moins une extraction du principe actif des bourgeons de peuplier Populus nigra L. à l'eau à température voisine de la température ambiante,• at least one extraction of the active ingredient from Populus nigra L. poplar buds with water at a temperature close to room temperature,
• concentration totale ou partielle des solutions obtenues, • éventuellement dilution des concentrats liquides dans un solvant choisi par exemple dans le groupe formé par le propylène glycol, le butylène glycol, la
glycérine, dans des proportions eau/solvant comprises entre 10/90 et 90/10 v/v. • filtration des concentrats.• total or partial concentration of the solutions obtained, • optionally dilution of the liquid concentrates in a solvent chosen, for example, from the group formed by propylene glycol, butylene glycol, glycerin, in water / solvent proportions between 10/90 and 90/10 v / v. • filtration of concentrates.
L'extrait de bourgeons de peuplier utilisé pour mettre en œuvre la présente invention peut être obtenu selon le procédé suivant : les bourgeons de peuplier sont broyés puis placés dans un réacteur. La drogue est extraite avec de l'eau à une température voisine de la température ambiante, c'est-à-dire comprise entre 5°C et 35 °C . Les volumes d'eau utilisés varient de 5 à 20 parties. L'extraction peut être menée sous agitation ou statiquement pendant une durée variant de 1 à 10 heures.The poplar bud extract used to implement the present invention can be obtained according to the following process: the poplar buds are ground and then placed in a reactor. The drug is extracted with water at a temperature close to room temperature, that is to say between 5 ° C and 35 ° C. The volumes of water used vary from 5 to 20 parts. The extraction can be carried out with stirring or statically for a period varying from 1 to 10 hours.
Après extraction, les solutions sont récupérées par essorage ou par filtration. La drogue peut être re-extraite dans les mêmes conditions. Les solutions sont alors jointes. Les solutions obtenues peuvent être concentrées complètement de façon à obtenir une poudre.After extraction, the solutions are recovered by draining or by filtration. The drug can be re-extracted under the same conditions. The solutions are then attached. The solutions obtained can be concentrated completely so as to obtain a powder.
La concentration peut aussi être partielle de façon à obtenir un extrait dont la matière sèche varie de 2 à 50% p/p. Dans tous les cas, la concentration est effectuée sous pression réduite. Les concentrats liquides obtenus peuvent être utilisés tels quels ou dilués dans des solvants comme le propylène glycol, le butylène glycol, la glycérine dans des proportions variant de 10/90 à 90/10 v/v, eau/solvant. Les solutions obtenues sont filtrées de façon à obtenir une solution limpide. Les extraits obtenus sont examinés en chromatographie sur couche mince : les esters d'acides phénoliques sont absents (teneur inférieure à environ 0,1%), par contre on visualise des acides phénoliques sous forme libre comme l'acide caféique.The concentration can also be partial so as to obtain an extract whose dry matter varies from 2 to 50% w / w. In all cases, the concentration is carried out under reduced pressure. The liquid concentrates obtained can be used as such or diluted in solvents such as propylene glycol, butylene glycol, glycerin in proportions varying from 10/90 to 90/10 v / v, water / solvent. The solutions obtained are filtered so as to obtain a clear solution. The extracts obtained are examined by thin layer chromatography: the phenolic acid esters are absent (content less than about 0.1%), on the other hand, phenolic acids in free form are visualized such as caffeic acid.
La teneur en polyphenols est également dosée par dosage colométrique avec le réactif de Folin-Ciocalteu. Leur teneur varie selon les extraits de 5 à 20% par rapport à la matière sèche.The polyphenol content is also determined by colometric determination with the Folin-Ciocalteu reagent. Their content varies according to the extracts from 5 to 20% compared to the dry matter.
La présente invention concerne encore un procédé de préparation d'une association de squalane et d'un extrait de bourgeons de peuplier pour son utilisation en tant que médicament ou pour son utilisation pour préparer une composition cosmétique, telle que l'on mélange le squalane et l'extrait de bourgeons de peuplier.
Nous avons associé le squalane avec l'extrait aqueux de bourgeons de peuplier et avons démontré la potentialisation de l'activité anti-inflammatoire de l'extrait de bourgeons de peuplier par le squalane.The present invention also relates to a process for preparing a combination of squalane and an extract of poplar buds for its use as a medicament or for its use for preparing a cosmetic composition, such as mixing squalane and poplar bud extract. We have associated squalane with the aqueous extract of poplar buds and have demonstrated the potentiation of the anti-inflammatory activity of the extract of poplar buds by squalane.
La fonction barrière de la peau permet d'assurer une protection vis-à-vis de l'environnement extérieur, et les kératinocytes de l'épiderme peuvent directement répondre à une large variété d'agents irritants ou allergènes et participer activement aux processus inflammatoires et immunitaires cutanés, en particulier à travers l'élaboration de cytokines proinflammatoires et immunomodulatrices. Parmi ces molécules biologiquement actives, NL1 α (Interieukin 1 α) et le TNF α (Tumor Necrosis Factor α) sont considérées comme des cytokines primaires, leur libération étant insuffisante pour induire l'inflammation en vertu de leur induction de molécules d'adhésion au niveau des cellules endothéliales, de leur induction de facteurs chimiotactiques pour les leucocytes, et d'autres facteurs d'activation tel que l'interleukine 6, cytokine secondaire, qui est ainsi fortement impliquée dans l'amplification de la réponse inflammatoire. De plus, outre cette activation directe des kératinocytes au contact de molécules exogènes, d'autres facteurs régulent la réponse kératinocytaire pendant l'inflammation ; ce sont notamment les cytokines lymphocytaires telle l'interféron γ (IFN γ), produites par les cellules mononucléées infiltrées à ce moment-là dans le derme et capables de modifier significativement le microenvironnement cutané.The barrier function of the skin provides protection against the external environment, and the keratinocytes of the epidermis can directly respond to a wide variety of irritants or allergens and actively participate in inflammatory and cutaneous immune systems, in particular through the development of proinflammatory and immunomodulatory cytokines. Among these biologically active molecules, NL1 α (Interieukin 1 α) and TNF α (Tumor Necrosis Factor α) are considered to be primary cytokines, their release being insufficient to induce inflammation by virtue of their induction of molecules of adhesion to level of endothelial cells, their induction of chemotactic factors for leukocytes, and other activating factors such as interleukin 6, a secondary cytokine, which is thus strongly involved in the amplification of the inflammatory response. In addition, in addition to this direct activation of keratinocytes in contact with exogenous molecules, other factors regulate the keratinocyte response during inflammation; these are in particular lymphocyte cytokines such as interferon γ (IFN γ), produced by mononuclear cells infiltrated at that time in the dermis and capable of significantly modifying the cutaneous microenvironment.
Les exemples qui suivent illustrent l'invention sans en limiter la portée.The following examples illustrate the invention without limiting its scope.
Exemple 1Example 1
100 kg de bourgeons de peuplier broyés sont introduits dans un réacteur avec 700 litres d'eau. L'extraction est réalisée à température ambiante (20°C) sous agitation pendant 1 heure. La drogue épuisée est écartée par essorage. Les solutions sont concentrées sous pression réduite jusqu'à l'obtention d'une matière sèche de 5% p/p.100 kg of crushed poplar buds are introduced into a reactor with 700 liters of water. The extraction is carried out at ambient temperature (20 ° C.) with stirring for 1 hour. The exhausted drug is removed by spin. The solutions are concentrated under reduced pressure until a dry matter of 5% w / w is obtained.
Du propylène glycol est ajouté de façon à obtenir une matière sèche de 2% p/p. L'extrait obtenu est filtré, on obtient 350 kg d'extrait. L'absence d'esters d'acide phénolique est vérifiée par chromatographie sur couche mince ainsi que la présence d'acide caféique. Le dosage en polyphenols permet de quantifier leur teneur à 10% par rapport à la matière sèche de l'extrait.
Exemple 2Propylene glycol is added so as to obtain a dry matter of 2% w / w. The extract obtained is filtered, 350 kg of extract are obtained. The absence of phenolic acid esters is verified by thin layer chromatography as well as the presence of caffeic acid. The polyphenol dosage makes it possible to quantify their content at 10% relative to the dry matter of the extract. Example 2
10 kg de bourgeon de peuplier broyé sont extraits par 100kg d'eau à température ambiante (20°C) et sous agitation pendant 2 heures. La drogue épuisée est éliminée par essorage. La solution obtenue est concentrée sous pression réduite puis séchée en étuve jusqu'à l'obtention de 2kg de poudre de couleur brune. La présence d'acide caféique et l'absence d'esters d'acide phénolique sont déterminées par chromatographie sur couche mince. La teneur en polyphenols est de 15%.10 kg of crushed poplar bud are extracted with 100kg of water at room temperature (20 ° C) and with stirring for 2 hours. Spent drugs are removed by spin. The solution obtained is concentrated under reduced pressure and then dried in an oven until 2 kg of brown powder are obtained. The presence of caffeic acid and the absence of phenolic acid esters are determined by thin layer chromatography. The polyphenol content is 15%.
L'étude du pouvoir allergisant de l'extrait de bourgeons de peuplier a été effectuée sur 30 cobayes après application d'un extrait hydroglycolique à 2% de résidu sec. L'effet recherché a été maximisé par injection d'adjuvant complet de Freund. Les animaux ont été exposés à l'extrait par injection intradermique et application topique dans des conditions irritantes (exposition d'induction). Après une période de repos de 10 à 14 jours (période d'induction), les animaux ont été exposés à une dose de déclenchement.The allergenicity study of the poplar bud extract was carried out on 30 guinea pigs after application of a hydroglycolic extract with 2% dry residue. The desired effect was maximized by injection of complete Freund's adjuvant. The animals were exposed to the extract by intradermal injection and topical application under irritant conditions (induction exposure). After a rest period of 10 to 14 days (induction period), the animals were exposed to a trigger dose.
L'étendue et le degré de la réaction cutanée des animaux ont été comparés à ceux de la réaction observée chez les animaux témoins ne recevant que le véhicule lors de l'induction et soumis à l'exposition de déclenchement. L'extrait de bourgeons de peuplier a été testé pur, à 50%, à 25% et 12,5% p/p.The extent and degree of the skin reaction of the animals were compared to that of the reaction observed in control animals receiving only the vehicle during induction and subjected to the triggering exposure. The poplar bud extract was tested pure, 50%, 25% and 12.5% w / w.
A aucune de ces concentrations l'extrait de bourgeons de peuplier n'a provoqué de réaction allergique chez les animaux.At none of these concentrations did the poplar bud extract cause an allergic reaction in animals.
Nous nous sommes proposés d'évaluer les propriétés anti-inflammatoires de l'extrait de bourgeons de peuplier et du squalane sur le modèle de libération d'interleukine 6 par les kératinocytes humains stimulés par l'interféron γ.We set out to evaluate the anti-inflammatory properties of poplar bud extract and squalane on the model of interleukin 6 release by human keratinocytes stimulated by interferon γ.
Les kératinocytes sont exposés dans un milieu de culture adéquat pendant 24 heures à l'extrait de bourgeons de peuplier à des concentrations de 0,03%, 0,05% et 0,08% p/p. Le squalane est testé à la concentration de 1mg/ml ; puis, ces deux produits sont testés associés aux concentrations suivantes : extrait de bourgeons de peuplier 0,03% p/p + squalane 1mg/ml et bourgeons de peuplier 0,05% p/p + squalane 1mg/ml.
La stimulation à l'interféron γ est effectuée à une concentration de 500 unités/ml pendant 24 heures supplémentaires.The keratinocytes are exposed in an adequate culture medium for 24 hours to the extract of poplar buds at concentrations of 0.03%, 0.05% and 0.08% w / w. Squalane is tested at a concentration of 1 mg / ml; then, these two products are tested associated with the following concentrations: poplar bud extract 0.03% w / w + squalane 1mg / ml and poplar buds 0.05% w / w + squalane 1mg / ml. Stimulation with interferon γ is carried out at a concentration of 500 units / ml for an additional 24 hours.
Enfin, les milieux de culture sont récupérés par centrifugation et la production d'interleukine 6 est mesurée par kit Eiisa.Finally, the culture media are recovered by centrifugation and the production of interleukin 6 is measured by Eiisa kit.
Cette étude in vitro d'évaluation, après exposition à l'extrait de bourgeons de peuplier, de la libération d'interleukine 6 par les kératinocytes humains stimulés par l'interféron γ montre que :This in vitro study of evaluation, after exposure to the extract of poplar buds, of the release of interleukin 6 by human keratinocytes stimulated by interferon γ shows that:
- L'extrait de bourgeons de peuplier inhibe significativement et de façon dose-dépendante la production d'interleukine 6 induite par l'interféron γ : -29% et -66% d'inhibition aux concentrations respectives de 0,05% et 0,08%.- The poplar bud extract significantly and dose-dependent inhibits the production of interleukin 6 induced by interferon γ: -29% and -66% inhibition at the respective concentrations of 0.05% and 0, 08%.
- La concentration 0,03% de bourgeons de peuplier ne module pas la production d'interleukine 6.- The 0.03% concentration of poplar buds does not modulate the production of interleukin 6.
- Le squalane à la concentration 1mg/ml évaluée présente une activité inhibitrice très discrète (-2%) et non significative sur la production d'interleukine 6.- Squalane at the concentration of 1 mg / ml evaluated has a very discreet inhibitory activity (-2%) and not significant on the production of interleukin 6.
- L'association des 2 actifs bourgeons de peuplier/squalane montre une potentialisation de l'activité inhibitrice sur la production d'interleukine 6, ceci aux 2 concentrations 0,03% et 0,05% de bourgeons de peuplier associées au squalane 1mg/ml :- The association of the 2 active poplar / squalane buds shows a potentiation of the inhibitory activity on the production of interleukin 6, this at the 2 concentrations 0.03% and 0.05% of poplar buds associated with squalane 1 mg / ml:
L'extrait de bourgeons de peuplier (0,03%) associé au squalane (1 mg/ml) présente une activité inhibitrice de la production d'interleukine 6 potentialisée → -11% (contre 1% qu'on aurait pu attendre dans un effet additif).
L'extrait de bourgeons de peuplier (0,05%) associé au squalane (1 mg/ml) présente une activité inhibitrice de la production d'interleukine 6 potentialisée → -39% (contre -31% qu'on aurait pu attendre dans un effet additif).The poplar bud extract (0.03%) associated with squalane (1 mg / ml) has an inhibitory activity on the production of potentiated interleukin 6 → -11% (compared to 1% that one would have expected in a additive effect). The extract of poplar buds (0.05%) associated with squalane (1 mg / ml) has an inhibitory activity on the production of interleukin 6 potentiated → -39% (against -31% that one could have expected in an additive effect).
Cette étude permet de montrer les effets synergiques de l'extrait de bourgeons de peuplier et du squalane en terme d'inhibition de la production d'interleukine 6 par les kératinocytes humains stimulés par de l'interféron γ.This study shows the synergistic effects of poplar bud extract and squalane in terms of inhibition of the production of interleukin 6 by human keratinocytes stimulated by interferon γ.
Dans cette étude, nous avons démontré que l'extrait aqueux de bourgeons de peuplier, solubilisé ou non dans un solvant, comme le propylène glycol, le butylène glycol et la glycérine, caractérisé par la présence d'acide caféique, par sa teneur en polyphenols (5 à 20% par rapport à la matière sèche de l'extrait) et par l'absence d'esters d'acides phénoliques (teneur inférieure à environ 0,1%), ne présente aucun pouvoir allergisant et conserve son activité anti-inflammatoire.In this study, we have demonstrated that the aqueous extract of poplar buds, whether or not dissolved in a solvent, such as propylene glycol, butylene glycol and glycerin, characterized by the presence of caffeic acid, by its polyphenol content (5 to 20% compared to the dry matter of the extract) and by the absence of phenolic acid esters (content less than about 0.1%), has no allergenic power and retains its anti- inflammatory.
De plus, l'association avec le phytosqualane augmente cette activité antiinflammatoire.In addition, the association with phytosqualane increases this anti-inflammatory activity.
Les exemples de formulations galéniques présentées ci-après illustrent l'invention sans toutefois en limiter la portée.
The examples of galenical formulations presented below illustrate the invention without however limiting its scope.
Exemple 1 SYNDET PEAUX SENSIBLESExample 1 SYNDET SENSITIVE SKIN
SULFOSUCCINATE DE LAURYL DISODIQUE 24.50%LAURYL SODIUM SULFOSUCCINATE 24.50%
SULFATE DE LAURYL DISODIQUE 24.50%DISODIUM LAURYL SULFATE 24.50%
AMIDON DE MAIS 18.2652%CORN STARCH 18.2652%
ALCOOL CETEARYLIQUE 9.329%CETEARYLIC ALCOHOL 9.329%
PARAFFINE 8.329%PARAFFIN 8.329%
SQUALANE 1.00%SQUALANE 1.00%
EAU 7.265%WATER 7.265%
EXT. BOURGEON DE PEUPLIER 0.200%EXT. POPLAR BUDS 0.200%
ACIDE STEARIQUE 4.419%STEARIC ACID 4.419%
HUILE DE CALENDULA 1.000%CALENDULA OIL 1.000%
ACIDE CITRIQUE 0.2946%CITRIC ACID 0.2946%
ALCOOL PHENETHYLIQUE 0.100%0.100% PHENETHYL ALCOHOL
EXT. D'AMANDE DOUCE 0.500%EXT. SWEET ALMOND 0.500%
DIOXIDE DE TITANE 0.2982%TITANIUM DIOXIDE 0.2982%
Exemple 2 SAVON DE TOILETTEExample 2 TOILET SOAP
HUILE D'AMANDE DOUCE RAFFINEE 0.50%REFINED SWEET ALMOND OIL 0.50%
EXT. BOURGEON DE PEUPLIER 0.25%EXT. POPLAR BUDDING 0.25%
SQUALANE 1.05%SQUALANE 1.05%
PARFUM 2.00%PERFUME 2.00%
COPEAUX SAVONS 96.0% Eau q.s.p. 100CHIPS SOAP 96.0% Water q.s.p. 100
Exemple 3 GEL DE DOUCHEEXAMPLE 3 SHOWER GEL
SQUALANE 0.10%SQUALANE 0.10%
EXT. BOURGEON DE PEUPLIER 1.00%EXT. POPLAR BUG 1.00%
GLYCEROL 1.00%GLYCEROL 1.00%
SULFATE DE LAURETH SODIQUE 20.0%SODIUM LAURETH SULPHATE 20.0%
ORAMIX NS10 8% TEGOBETAINE F50 12.0%ORAMIX NS10 8% TEGOBETAINE F50 12.0%
ELFACOS GT 282 S 1.00%
OPACIFIANT E 295 0.50%ELFACOS GT 282 S 1.00% OPACIFIER E 295 0.50%
NAOH 0.05%NAOH 0.05%
DMDM HYDANTOIN 0.20%DMDM HYDANTOIN 0.20%
PARFUM 1.00% BENZOPHENONE-4 0.10%PERFUME 1.00% BENZOPHENONE-4 0.10%
EAU 55.05%WATER 55.05%
Exemple 4 LAIT CORPORELEXAMPLE 4 BODY MILK
EXTRAIT FLUIDE DE BOURGEON DE PEUPLIER 0,1 à 1 gFLUID EXTRACT OF POPLAR BUD 0.1 to 1 g
SQUALANE 0,5 à 5 gSQUALANE 0.5 to 5 g
VITAMINE E ACETATE 0,2 à 0,5 gVITAMIN E ACETATE 0.2 to 0.5 g
MONOSTEARATE DE GLYCEROL OE 100 MOLES 5 gGLYCEROL MONOSTEARATE OE 100 MOLES 5 g
PARAFFINE LIQUIDE 10 g DECAMETHYL CYCLOPENTASILOXANE 5 gLIQUID PARAFFIN 10 g DECAMETHYL CYCLOPENTASILOXANE 5 g
POLYMERE CARBOXYVINYLIQUE 0,2 gCARBOXYVINYL POLYMER 0.2 g
TRIETHANOLAMINE 0,25 g CONSERVATEURS q.s. PARFUM q.s. EAU POTABLE q.s.p. 100 gTRIETHANOLAMINE 0.25 g PRESERVATIVES q.s. PERFUME q.s. DRINKING WATER q.s.p. 100g
Exemple 5 CREME CORPORELLE NUTRITIVE ET APAISANTEEXAMPLE 5 NUTRITIVE AND SOOTHING BODY CREAM
EXTRAIT FLUIDE DE BOURGEONS DE PEUPLIER 0,1 à 1 g SQUALANE 0,5 à 5 gFLUID EXTRACT OF POPLAR BEANS 0.1 to 1 g SQUALANE 0.5 to 5 g
DIMETHICONE COPOLYOL ET CYCLOMETHICONE 5 gDIMETHICONE COPOLYOL AND CYCLOMETHICONE 5 g
PALMITATE D'ISOPROPYLE 2 gISOPROPYLE PALMITATE 2 g
PARAFFINE LIQUIDE 10 gLIQUID PARAFFIN 10 g
GLYCERINE 10 g POLYETHYLENE GLYCOL400 10 gGLYCERINE 10 g POLYETHYLENE GLYCOL400 10 g
CHLORURE DE SODIUM 1 g CONSERVATEURS q.s. PARFUM q.s.SODIUM CHLORIDE 1 g PRESERVATIVES q.s. PERFUME q.s.
EAU POTABLE q.s.p. 100 g
Exemple 6 CREME REPARATRICE POUR LESDRINKING WATER qs 100 g EXAMPLE 6 REPAIRING CREAM FOR
MAINS OU SOIN APRES EPILATIONHANDS OR CARE AFTER HAIR REMOVAL
EXTRAIT FLUIDE DE BOURGEONS DE PEUPLIER 0,1 à 5 gFLUID EXTRACT OF POPLAR BEANS 0.1 to 5 g
SQUALANE 0,5 à 5 gSQUALANE 0.5 to 5 g
STEARATE DE GLYCEROL OE 10 gGLYCEROL STEARATE OE 10 g
ALCOOL CETO STEARYLIQUE 1 g HYDROXYPROLINE 0,5 gCETO STEARYLIQUE ALCOHOL 1 g HYDROXYPROLINE 0.5 g
HUILE DE PARAFFINE EPAISSE 7 gTHICK PARAFFIN OIL 7 g
GLYCEROL 5 g CONSERVATEURS q.s. PARFUM q.s. EAU POTABLE q.s.p. 100 g
GLYCEROL 5 g PRESERVATIVES q.s. PERFUME q.s. DRINKING WATER q.s.p. 100g
Claims
1. Association de squalane et d'un extrait de bourgeons de peuplier Populus nigra L. non allergisant tel qu'il contient des polyphenols en quantité comprise entre 5 et 20% par rapport à la matière sèche de l'extrait, des acides phénoliques et qu'il ne contient pratiquement pas d'esters d'acides phénoliques pour son utilisation en tant que médicament.1. Association of squalane and an extract of populus buds Populus nigra L. non-allergenic as it contains polyphenols in an amount between 5 and 20% relative to the dry matter of the extract, phenolic acids and that it contains practically no esters of phenolic acids for use as a medicament.
2. Association selon la revendication 1 caractérisée en ce que les acides phénoliques sont des acides hydroxy-cinnamiques et les esters d'acides phénoliques sont des esters d'acides hydroxy-cinnamiques.2. Association according to claim 1 characterized in that the phenolic acids are hydroxy-cinnamic acids and the esters of phenolic acids are esters of hydroxy-cinnamic acids.
3. Association selon la revendication 1 ou 2 caractérisée en ce que la teneur en extrait de bourgeons de peuplier est comprise entre 0,1% et 5% poids et la teneur en squalane est comprise entre 0,1% et 10% poids.3. Association according to claim 1 or 2 characterized in that the content of poplar bud extract is between 0.1% and 5% by weight and the squalane content is between 0.1% and 10% by weight.
4. Association selon l'une des revendications 1 à 3 telle que l'extrait de bourgeons de peuplier Populus nigra L est obtenu en effectuant les étapes suivantes:4. Association according to one of claims 1 to 3 such that the poplar bud extract Populus nigra L is obtained by performing the following steps:
• au moins une extraction du principe actif des bourgeons de peuplier Populus nigra L. à l'eau à une température voisine de la température ambiante, • concentration totale ou partielle des solutions obtenues,• at least one extraction of the active ingredient from Populus nigra L. poplar buds with water at a temperature close to room temperature, • total or partial concentration of the solutions obtained,
• filtration des concentrats.• filtration of concentrates.
5. Association selon la revendication 4 telle que l'extrait de bourgeons de peuplier Populus nigra L est obtenu en effectuant une dilution des concentrats liquides dans un solvant, de préférence choisi dans le groupe formé par le propyiène glycol, le butylène glycol, la glycérine, dans des proportions eau/solvant comprises entre 10/90 et 90/10 v/v, après l'étape de concentration des solutions. 5. Association according to claim 4 such that the poplar bud extract Populus nigra L is obtained by diluting the liquid concentrates in a solvent, preferably chosen from the group formed by propyiene glycol, butylene glycol, glycerin , in water / solvent proportions of between 10/90 and 90/10 v / v, after the solution concentration step.
6. Association selon l'une des revendications 1 à 5 pour son utilisation en tant que médicament anti-inflammatoire.6. Association according to one of claims 1 to 5 for its use as an anti-inflammatory drug.
7. Utilisation d'une association de squalane et d'un extrait de bourgeons de peuplier Populus nigra L. non allergisant tel qu'il contient des polyphenols en quantité comprise entre 5 et 20% par rapport à la matière sèche de l'extrait, des acides phénoliques et qu'il ne contient pratiquement pas d'esters d'acides phénoliques pour préparer une composition cosmétique.7. Use of a combination of squalane and a non-allergenic Populus nigra L. poplar bud extract such as it contains polyphenols in an amount of between 5 and 20% relative to the dry matter of the extract, phenolic acids and that it contains practically no esters of phenolic acids to prepare a cosmetic composition.
8. Utilisation d'une association pour préparer une composition cosmétique selon la revendication 7 caractérisée en ce que les acides phénoliques sont des acides hydroxy-cinnamiques et les esters d'acides phénoliques sont des esters d'acides hydroxy-cinnamiques.8. Use of a combination to prepare a cosmetic composition according to claim 7 characterized in that the phenolic acids are hydroxy-cinnamic acids and the esters of phenolic acids are esters of hydroxy-cinnamic acids.
9. Utilisation d'une association pour préparer une composition cosmétique selon la revendication 7 ou 8 caractérisée en ce que la teneur en extrait de bourgeons de peuplier est comprise entre 0,1% et 5% poids et la teneur en squalane est comprise entre 0,1% et 10% poids.9. Use of a combination to prepare a cosmetic composition according to claim 7 or 8 characterized in that the content of poplar bud extract is between 0.1% and 5% by weight and the squalane content is between 0 , 1% and 10% by weight.
10. Utilisation d'une association pour préparer une composition cosmétique selon l'une des revendications 7 à 9 telle que l'extrait de bourgeons de peuplier Populus nigra L est obtenu en effectuant les étapes suivantes:10. Use of a combination to prepare a cosmetic composition according to one of claims 7 to 9 such that the poplar bud extract Populus nigra L is obtained by carrying out the following steps:
• au moins une extraction du principe actif des bourgeons de peuplier Populus nigra L à l'eau à une température voisine de la température ambiante,At least one extraction of the active principle from Populus nigra L poplar buds with water at a temperature close to room temperature,
• concentration totale ou partielle des solutions obtenues,• total or partial concentration of the solutions obtained,
• filtration des concentrats.• filtration of concentrates.
11. Utilisation d'une association pour préparer une composition cosmétique selon la revendication 10 telle que l'extrait de bourgeons de peuplier11. Use of a combination to prepare a cosmetic composition according to claim 10 such as the poplar bud extract
Populus nigra L. est obtenu en effectuant une dilution des concentrats liquides dans un solvant de préférence choisi dans le groupe formé par le propylène glycol, le butylène glycol, la glycérine, dans des proportions eau/solvant comprises entre 10/90 et 90/10 v/v, après l'étape de concentration des solutions. Populus nigra L. is obtained by diluting the liquid concentrates in a solvent preferably chosen from the group formed by propylene glycol, butylene glycol, glycerin, in water / solvent proportions between 10/90 and 90/10 v / v, after the solution concentration step.
2. Procédé de traitement cosmétique caractérisé en ce qu'il comprend l'application topique d'une composition cosmétique préparée en utilisant l'association selon l'une des revendications 7 à 11. 2. Cosmetic treatment method characterized in that it comprises the topical application of a cosmetic composition prepared using the combination according to one of claims 7 to 11.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR99/05696 | 1999-05-05 | ||
FR9905696A FR2793141B1 (en) | 1999-05-05 | 1999-05-05 | EXTRACT OF POPLAR BEANS AND ITS ASSOCIATION WITH SQUALANE FOR USE AS AN ANTI-INFLAMMATORY MEDICINAL PRODUCT AND IN A COSMETIC TREATMENT PROCESS |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000067767A1 true WO2000067767A1 (en) | 2000-11-16 |
Family
ID=9545228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/001222 WO2000067767A1 (en) | 1999-05-05 | 2000-05-05 | Poplar bud extract and its combination with squalane as anti-inflammatory medicine |
Country Status (2)
Country | Link |
---|---|
FR (1) | FR2793141B1 (en) |
WO (1) | WO2000067767A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2869229A1 (en) * | 2004-04-26 | 2005-10-28 | Sederma Soc Par Actions Simpli | USE OF A INDUCER OF UGT BY TOPIC |
WO2006068778A3 (en) * | 2004-12-22 | 2006-08-31 | Avon Prod Inc | The use of plant extracts to prevent and/or reduce the signs of subjective discomfort and/or irritation in the topical application of cosmetic products |
CN102504036A (en) * | 2011-10-27 | 2012-06-20 | 长葛市蜂业协会 | Processing technology for gum |
ITUA20163755A1 (en) * | 2016-05-24 | 2017-11-24 | Aboca Spa Societa Agricola | COMPOSITIONS BASED ON GEMS OF POPLAR AND THEIR USES |
CN112138057A (en) * | 2020-09-30 | 2020-12-29 | 华中农业大学 | Use of poplar bud extract in preparation of lipoxygenase inhibitor |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2962039B1 (en) | 2010-07-05 | 2016-11-04 | Gattefosse S A S | USE OF A BALSAMIFERA POPULUS EXTRACT AS A DEPIGMENTING AGENT |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987006834A1 (en) * | 1986-05-12 | 1987-11-19 | Michel Fontaine | Medicaments for the prevention and treatment of alcoholic toxicomania and methods for obtaining them |
FR2696093A1 (en) * | 1992-09-29 | 1994-04-01 | Joanny Labo Pharma Fabi | Compsn. contg. 3-methyl-2-butenyl caffeate - for treating herpes |
JPH07188045A (en) * | 1993-12-28 | 1995-07-25 | Mikimoto Pharmaceut Co Ltd | Antiplasmin agent |
-
1999
- 1999-05-05 FR FR9905696A patent/FR2793141B1/en not_active Expired - Lifetime
-
2000
- 2000-05-05 WO PCT/FR2000/001222 patent/WO2000067767A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987006834A1 (en) * | 1986-05-12 | 1987-11-19 | Michel Fontaine | Medicaments for the prevention and treatment of alcoholic toxicomania and methods for obtaining them |
FR2696093A1 (en) * | 1992-09-29 | 1994-04-01 | Joanny Labo Pharma Fabi | Compsn. contg. 3-methyl-2-butenyl caffeate - for treating herpes |
JPH07188045A (en) * | 1993-12-28 | 1995-07-25 | Mikimoto Pharmaceut Co Ltd | Antiplasmin agent |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Section Ch Week 199538, Derwent World Patents Index; Class B04, AN 1995-290316, XP002146043 * |
SOKOLNICKA I ET AL: "IMMUNOSTIMULATORY EFFECTS OF WATER-SOLUBLE EXTRACTS OF POPLAR BUDS AND LEAVES AND THEIR POLYPHENOLIC COMPOUNDS", INTERNATIONAL JOURNAL OF IMMUNOTHERAPY,CH,BIOSCIENCE EDIPRINT INC., CAROUGE-GENEVA, vol. 10, no. 2, 1994, pages 83 - 88, XP000867202, ISSN: 0255-9625 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8530426B2 (en) | 2004-04-26 | 2013-09-10 | Sederma Sas | Cosmetic or dermopharmaceutical composition comprising at least one UDP glucuronosyl transferase (UGT) enzymes inducer |
WO2005102266A1 (en) * | 2004-04-26 | 2005-11-03 | Sederma, Sas | Cosmetic or dermopharmaceutical composition comprising at least one udp glucuronosyl transferase (ugt) enzymes inducer |
FR2869229A1 (en) * | 2004-04-26 | 2005-10-28 | Sederma Soc Par Actions Simpli | USE OF A INDUCER OF UGT BY TOPIC |
WO2006068778A3 (en) * | 2004-12-22 | 2006-08-31 | Avon Prod Inc | The use of plant extracts to prevent and/or reduce the signs of subjective discomfort and/or irritation in the topical application of cosmetic products |
US8221766B2 (en) | 2004-12-22 | 2012-07-17 | Avon Products, Inc. | Use of plant extracts to prevent and/or reduce the signs of subjective discomfort and/or irritation in the topical application of cosmetic products |
CN101048134B (en) * | 2004-12-22 | 2012-09-26 | 雅芳产品公司 | The use of plant extracts to prevent and/or reduce the signs of subjective discomfort and/or irritation in the topical application of cosmetic products |
CN102504036A (en) * | 2011-10-27 | 2012-06-20 | 长葛市蜂业协会 | Processing technology for gum |
ITUA20163755A1 (en) * | 2016-05-24 | 2017-11-24 | Aboca Spa Societa Agricola | COMPOSITIONS BASED ON GEMS OF POPLAR AND THEIR USES |
WO2017203414A1 (en) * | 2016-05-24 | 2017-11-30 | Aboca S.P.A. Società Agricola | Compositions comprising extract of poplar buds and uses thereof |
CN109152806A (en) * | 2016-05-24 | 2019-01-04 | 阿波卡-阿格里科拉共同股份公司 | Composition and application thereof comprising gemma populi extract |
AU2017271261B2 (en) * | 2016-05-24 | 2020-04-09 | Aboca S.P.A. Società Agricola | Compositions comprising extract of poplar buds and uses thereof |
US11839638B2 (en) | 2016-05-24 | 2023-12-12 | Aboca S.P.A. Società Agricola | Compositions comprising extract of poplar buds and uses thereof |
CN112138057A (en) * | 2020-09-30 | 2020-12-29 | 华中农业大学 | Use of poplar bud extract in preparation of lipoxygenase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
FR2793141A1 (en) | 2000-11-10 |
FR2793141B1 (en) | 2003-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2969274B2 (en) | Anti-roughening agent | |
JP4947034B2 (en) | Polylysine preparation and cosmetic composition containing the same | |
MX2007005886A (en) | Pharmaceutical and therapeutic compositions derived from garcinia mangostana l plant. | |
JPH07278003A (en) | Testosterone-5alpha-reductase inhibitor | |
EP2654762B1 (en) | Extract of the aerial parts of gynandropsis gynandra and cosmetic, dermatoligic and pharmaceutic compositions comprising the extract | |
EP3737352A1 (en) | Cosmetic use of a protein extract of moringa oleifera seeds | |
KR20110082292A (en) | Extract of Hwangchil Tree for Atopic and Acne Skin | |
JP2000247897A (en) | Cosmetic composition | |
JP3722511B2 (en) | Skin preparations and bath preparations | |
JP2006137690A (en) | Skin external preparation and hyaluronic acid production accelerator | |
EP1429720A2 (en) | Cosmetic composition for human skin and hair care | |
JP3118020B2 (en) | Cosmetics | |
JP2001081037A (en) | Cosmetic composition | |
FR2755015A1 (en) | USE OF A FLAVONOIDIC EXTRACT OF GINKGO BILOBA SUBSTANTIALLY FREE FROM TERPENES IN THE ORAL DOMAIN AND COMPOSITION CONTAINING SUCH EXTRACT | |
JP2003104865A (en) | Skin care preparation | |
JP2002316937A (en) | Plant extract-containing anti-allergic agent | |
WO2000067767A1 (en) | Poplar bud extract and its combination with squalane as anti-inflammatory medicine | |
JP3319870B2 (en) | Skin external composition and bath agent | |
EP1280542A1 (en) | Use of a cell extract of at least a plant of the family pontederiaceae as anti-pollution agent | |
JP4197194B2 (en) | Oral administration agent for intercellular adhesion suppression | |
JP2001106619A (en) | Cosmetic composition | |
KR100946584B1 (en) | Cosmetic composition for astringent and skin irritation containing fruit extract and Blue Lotus extract | |
JP4716497B2 (en) | External preparation for skin and hyaluronidase inhibitor | |
EP1521586A2 (en) | Use of a chrysanthellum extract | |
FR2859102A1 (en) | USE OF A RHODIOLA CRENULATA EXTRACT BY TOPIC |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |